Shanghai Ark Biopharmaceutical announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment of idiopathic...
National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market. Bireociclib tablets (tra...
Invisalign® Palatal Expanders offer doctors a removeable, safe, and clinically effective alternative to traditional palatal expanders. With Invi...
Core Illumina revenue of $1.04 billion for Q1 2025, down 1% from Q1 2024 (flat on a constant currency basis) GAAP operating margin...
Chengdu Origen Biotechnology Co., Ltd. (“Chengdu Origen”) and Vanotech Ltd. (“Vanotech”) announced the first patient dosed ...
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced that its new generation...
Innovent Biologics, Inc. ("Innovent"), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for t...
From April 25 to April 30, 2025, U.S. time, ImmVira presented the Phase I clinical results of its oncolytic Herpes Simplex Virus ("oHSV") product MVR-...
Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and...
HUTCHMED (China) Limited (“HUTCHMED”) announces that it has completed enrollment of the registration phase of its Phase II trial of savol...
Akeso, Inc. is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, has received marketing approval from ...
Partnership with specialist life science distributor establishes sales channel in high-demand market and strengthens global network Hypothermic pres...
Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug Conjug...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that results from a Phase 3 registrational clinical study evaluating...
© 2025 Biopharma Boardroom. All Rights Reserved.
